Harrow Health, Inc. (HROW)
HROW Stock Price Chart
Explore Harrow Health, Inc. interactive price chart. Choose custom timeframes to analyze HROW price movements and trends.
HROW Company Profile
Discover essential business fundamentals and corporate details for Harrow Health, Inc. (HROW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Sept 2007
Employees
382.00
Website
https://www.harrowinc.comCEO
Mark L. Baum
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Financial Timeline
Browse a chronological timeline of Harrow Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is $0.15.
Earnings released on 11 Aug 2025
EPS came in at $0.24 falling short of the estimated $0.29 by -17.24%, while revenue for the quarter reached $63.74M , missing expectations by -13.80%.
Earnings released on 8 May 2025
EPS came in at -$0.38 falling short of the estimated $0.02 by -2.00K%, while revenue for the quarter reached $47.83M , missing expectations by -29.53%.
Earnings released on 27 Mar 2025
EPS came in at $0.25 surpassing the estimated $0.11 by +127.27%, while revenue for the quarter reached $66.83M , beating expectations by +14.42%.
Earnings released on 13 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.05 by -140.00%, while revenue for the quarter reached $49.26M , missing expectations by -16.64%.
Earnings released on 7 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.25 by +48.00%, while revenue for the quarter reached $48.94M , missing expectations by -0.25%.
Earnings released on 13 May 2024
EPS came in at -$0.28 falling short of the estimated -$0.25 by -12.00%, while revenue for the quarter reached $34.59M , missing expectations by -7.20%.
Earnings released on 19 Mar 2024
EPS came in at -$0.27 falling short of the estimated -$0.05 by -455.56%, while revenue for the quarter reached $36.36M , missing expectations by -3.98%.
Earnings released on 13 Nov 2023
EPS came in at -$0.09 falling short of the estimated -$0.02 by -467.82%, while revenue for the quarter reached $34.27M , missing expectations by -9.50%.
Earnings released on 9 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -250.26%, while revenue for the quarter reached $33.47M , missing expectations by -11.94%.
Earnings released on 11 May 2023
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $26.10M , beating expectations by +3.79%.
Earnings released on 23 Mar 2023
EPS came in at $0.07 surpassing the estimated -$0.15 by +146.67%, while revenue for the quarter reached $20.33M , missing expectations by -5.00%.
Earnings released on 14 Nov 2022
EPS came in at -$0.06 falling short of the estimated -$0.00 by -9.58K%, while revenue for the quarter reached $22.82M , missing expectations by -1.39%.
Earnings released on 9 Aug 2022
EPS came in at $0.01 surpassing the estimated -$0.00 by +3.33K%, while revenue for the quarter reached $23.32M , beating expectations by +5.66%.
Earnings released on 5 May 2022
EPS came in at $0.03 surpassing the estimated $0.01 by +185.71%, while revenue for the quarter reached $22.12M , beating expectations by +13.53%.
Earnings released on 10 Mar 2022
EPS came in at -$0.01 falling short of the estimated $0.08 by -112.50%, while revenue for the quarter reached $20.19M , beating expectations by +4.34%.
Earnings released on 9 Nov 2021
EPS came in at $0.05 surpassing the estimated -$0.00 by +1.14K%, while revenue for the quarter reached $18.71M , beating expectations by +21.21%.
Earnings released on 10 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $18.13M , beating expectations by +15.43%.
Earnings released on 11 May 2021
EPS came in at $0.01 surpassing the estimated $0.00 by +128.31%, while revenue for the quarter reached $15.44M , beating expectations by +13.05%.
Earnings released on 8 Mar 2021
EPS came in at $0.04 surpassing the estimated $0.04 by +14.29%, while revenue for the quarter reached $14.60M , beating expectations by +1.00%.
Earnings released on 9 Nov 2020
EPS came in at $0.33 surpassing the estimated $0.17 by +94.12%, while revenue for the quarter reached $14.40M , missing expectations by -81.48%.
HROW Stock Performance
Access detailed HROW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.